Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00542776
Other study ID # 07-09-0345
Secondary ID
Status Completed
Phase N/A
First received October 9, 2007
Last updated April 30, 2008
Start date October 2007
Est. completion date February 2008

Study information

Verified date December 2007
Source Children's Hospital Boston
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) on immunosuppressive therapy with IBD patients on aminosalicylates and healthy historical controls.


Description:

Influenza is an extremely contagious airborne disease caused by influenza viruses. It can cause mild to severe illness, and even death. Patients who have inflammatory bowel disease (IBD) have a higher risk of getting serious complications if they are infected. Current guidelines recommend the influenza vaccine for IBD patients. However, many IBD patients take immunosuppressive agents and we are uncertain as to their capacity to mount a truly protective response after vaccination. This is an important area of research because if IBD patients do not have an adequate immunological response, then we may need to enhance their response by increasing the dosage or giving booster shots.

Many clinicians who treat patients with autoimmune diseases are asking if the vaccine is safe and effective. Many IBD patients will receive the vaccine without proper studies being performed to answer these questions. The study we are proposing has important clinical and public health significance. It is a step toward answering the question whether vaccination with the influenza vaccine is safe in patients with IBD and if patients on different types of immunosuppressive medications respond similarly and if they respond as well as healthy controls to the vaccine. There are more than one million people in the United States who have been diagnosed with IBD. Thus, the information gained from this clinical study will provide important knowledge to physicians caring for immunocompromised patients who are considering vaccination.

Studies on the immunological response of immunocompromised patients (e.g., transplant, HIV, oncology, chronic renal failure, SLE) to the influenza vaccine have demonstrated that some of these patients develop antibody titers at a protective level within 4-6 weeks. However, the titers were decreased compared to healthy controls, especially if the immunocompromised patients were on immunosuppressive agents. The frequency of influenza in immunocompromised patients was lower after immunization and there were almost no major side effects from the vaccine.

There is little data on immune response to vaccination in children with IBD. One recently published study compared influenza titers before and after vaccination among 3 pediatric groups: IBD patients who received immunosuppressive therapy, IBD patients who did not receive immunosuppressive therapy, and healthy controls. All IBD patients in the study had a decrease in response to one of three influenza strains when compared to controls. IBD patients who received both immunomodulators and infliximab had a lower immune response rate to two influenza strains when compared to controls. There was no difference in immune response among IBD patients on immunomodulators only, IBD patients on ASA, and controls. There was no difference in rates of adverse events between IBD patients and controls

The primary aim of this research are to measure seroprotection in IBD patients who are on or off immunosuppressive agents after receiving the influenza vaccine. The hypothesis is that IBD patients on immunosuppression have impaired immunity, and therefore, will have a lower seroprotection rate after immunization compared to IBD patients not on immunosuppression. If data is available, we will also compare each group to historical healthy controls given the same vaccine. The secondary aims are to determine the antibody titer levels and side effects these patients have.

The patient population includes IBD patients who are off immunosuppression and IBD patients who are on immunosuppression. Recruiting approximately 75 patients per group will provide adequate power for the study. A blood sample will be taken from all IBD patients to evaluate baseline antibody levels and markers (e.g., CBC, ESR, albumin) before or immediately after immunization with the influenza vaccine. Lab tests will be redrawn at Month 1 (3-8 weeks) to evaluate the level of antibody titers and follow the markers. During the study, we will track basic laboratory measures, disease status by using the Pediatric Crohn's Disease Active Index or Modified Harvey-Bradshaw Score for UC, side effects and adverse events from the vaccinations.


Recruitment information / eligibility

Status Completed
Enrollment 146
Est. completion date February 2008
Est. primary completion date February 2008
Accepts healthy volunteers No
Gender Both
Age group 5 Years and older
Eligibility Inclusion Criteria:

1. Crohn's disease, ulcerative colitis, or indeterminate colitis diagnosed by standard clinical, radiographic, endoscopic, and histologic criteria.

2. Age 5 years and older

3. Actively or previously followed by a gastroenterologist at Children's Hospital Boston

4. On non-immunosuppressants (aminosalicylates, antibiotics, or no medications) and/or immunosuppressants (steroids, immunomodulators, TNF-alpha inhibitors) for the past 30 days. Standard concomitant medications (e.g. antihistamines, acetaminophen) will be allowed.

Exclusion Criteria:

1. History of bleeding disorder that would make hematoma likely (eg hemophilia, von Willebrand's disease)

2. Received influenza vaccination during the current influenza season

3. Contraindications to the influenza vaccine (such as severe allergic reaction to prior influenza vaccine)

4. Fever within 48 hr prior to injection

5. Receipt of another vaccination within 2 days of influenza vaccine dose (and no other vaccines planned for 2 days after influenza vaccine)

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
blood draw
drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)

Locations

Country Name City State
United States Children's Hospital Boston Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital Boston Thrasher Research Fund

Country where clinical trial is conducted

United States, 

References & Publications (9)

Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002 Dec;29(12):2555-7. — View Citation

Banic S, Koren S, Tomazic J, Vidmar L, Ihan A, Poljak M, Avsic-Zupanc A. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy. Acta Virol. 2001 Feb;45(1):39-44. — View Citation

Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, Crump C, Hayden FG. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis. 1996 Feb;22(2):295-302. — View Citation

Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003;37(1):71-6. — View Citation

Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA, Kallenberg CG, Bijl M. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006 Jul;65(7):913-8. Epub 2005 Dec 1. — View Citation

Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007 Jul;5(7):851-6. Epub 2007 Jun 4. — View Citation

Matsuzaki A, Suminoe A, Koga Y, Kinukawa N, Kusuhara K, Hara T. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer. 2005 Nov;45(6):831-7. — View Citation

Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, Beyer WE, Tilanus HW, Kemmeren MH, Metselaar HJ, de Man RA, Osterhaus AD. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol. 2000 May;61(1):85-93. — View Citation

Suga T, Niki H, Niikura M, Matsumoto Y, Nishimura T, Nakajima K, Miyazaki M, Endoh M, Nomoto Y, Sakai H. Influenza antibody titers after vaccination of chronic renal failure patients; before and during hemodialysis, or on continuous ambulatory peritoneal dialysis. Tokai J Exp Clin Med. 1990 May;15(2-3):245-51. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary seroprotection rate 3-8 weeks after vaccination No
Secondary vaccine-associated adverse events up to 8 weeks after vaccination Yes
Secondary antibody titer levels 3-8 weeks after vaccination No
See also
  Status Clinical Trial Phase
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Completed NCT01022749 - Efficacy Safety Study of Flu Vaccine in Immunodepression Patients Phase 3
Completed NCT02461758 - Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Phase 4
Completed NCT01095042 - Cognition and Emotion in the SII and IBD N/A
Completed NCT02778464 - Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
Completed NCT02256605 - Vitamin D3 Supplementation in Pediatric IBD: Weely vs Daily Dosing Regimens N/A
Recruiting NCT05078879 - Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency Phase 1
Completed NCT05596422 - A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)
Completed NCT02355834 - Faecal Incontinence iNtervention Study N/A
Not yet recruiting NCT01852097 - An Online Intervention to Address Barriers to IBD Medication Adherence N/A
Terminated NCT00325078 - Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease Phase 1/Phase 2
Terminated NCT03886753 - Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
Recruiting NCT04345393 - Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes N/A
Completed NCT01819766 - Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease N/A
Completed NCT01560819 - Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases Phase 1
Completed NCT00820365 - SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease Phase 2
Completed NCT02156557 - Study of KCC Peptide Application in the Colon Phase 1
Completed NCT01364896 - Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Terminated NCT00152620 - Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease N/A